CEFTRIAXONE SODIUM injection, powder, for solution

Country: Stati Uniti

Lingwa: Ingliż

Sors: NLM (National Library of Medicine)

Ingredjent attiv:

CEFTRIAXONE SODIUM (UNII: 023Z5BR09K) (CEFTRIAXONE - UNII:75J73V1629)

Disponibbli minn:

Qilu Pharmaceutical Co., Ltd.

INN (Isem Internazzjonali):

CEFTRIAXONE SODIUM

Kompożizzjoni:

CEFTRIAXONE 250 mg

Rotta amministrattiva:

INTRAMUSCULAR

Tip ta 'preskrizzjoni:

PRESCRIPTION DRUG

Indikazzjonijiet terapewtiċi:

Before instituting treatment with Ceftriaxone for injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for injection, USP and other antibacterial drugs, Ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused

Sommarju tal-prodott:

Ceftriaxone for injection, USP is supplied as a sterile crystalline powder in glass vials. The following packages are available: Vials containing 250 mg equivalent of ceftriaxone. Package of 10 (NDC 67184-1005-1). Vials containing 500 mg equivalent of ceftriaxone. Package of 10 (NDC 67184-1006-1). Vials containing 1 g equivalent of ceftriaxone. Package of 10 (NDC 67184-1007-1). Vials containing 2 g equivalent of ceftriaxone. Package of 10 (NDC 67184-1008-1). Vials containing 250 mg equivalent to ceftriaxone. Package of 1 (67184-1005-2). Vials containing 500 mg equivalent to ceftriaxone. Package of 1 (67184-1006-2). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.

L-istatus ta 'awtorizzazzjoni:

Abbreviated New Drug Application

Karatteristiċi tal-prodott

CEFTRIAXONE SODIUM- CEFTRIAXONE SODIUM INJECTION, POWDER, FOR SOLUTION
QILU PHARMACEUTICAL CO., LTD.
----------
CEFTRIAXONE FOR INJECTION, USP
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of Ceftriaxone for
injection, USP and other antibacterial drugs, Ceftriaxone for
injection, USP should be used only to treat
or prevent infections that are proven or strongly suspected to be
caused by bacteria.
DESCRIPTION
Ceftriaxone for injection, USP is a sterile, semisynthetic,
broad-spectrum cephalosporin antibiotic for
intravenous or intramuscular administration. Ceftriaxone sodium is
(6_R_,7_R_)-7-[2-(2-Amino-4-
thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-_as_-triazin-3-yl)thio]methyl]-
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7
-(_Z_)-(_O_-methyloxime), disodium salt,
sesquaterhydrate.
The chemical formula of ceftriaxone sodium is C
H N Na O S •3.5H O. It has a calculated
molecular weight of 661.59 and the following structural formula:
Ceftriaxone for injection, USP is a white to yellowish-orange
crystalline powder which is readily
soluble in water, sparingly soluble in methanol and very slightly
soluble in ethanol. The pH of a 1%
aqueous solution is approximately 6.7. The color of Ceftriaxone for
injection, USP solutions ranges
from light yellow to amber, depending on the length of storage,
concentration and diluent used. Each
vial contains ceftriaxone sodium equivalent to 250 mg, 500 mg, 1 g or
2 g of ceftriaxone activity.
Ceftriaxone for injection, USP contains approximately 83 mg (3.6 mEq)
of sodium per gram of
ceftriaxone activity.
CLINICAL PHARMACOLOGY
Average plasma concentrations of ceftriaxone following a single
30-minute intravenous (IV) infusion of
a 0.5, 1 or 2 g dose and intramuscular (IM) administration of a single
0.5 (250 mg/mL or 350 mg/mL
concentrations) or 1 g dose in healthy subjects are presented in Table
1.
TABLE 1 CEFTRIAXONE PLASMA CONCENTRATIONS AFTER SINGLE DOSE
ADMINISTRATION
DOS E/ROUTE
AVERAGE PLASMA C